{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:07:18Z","timestamp":1791612438857,"version":"4.3.4"},"reference-count":31,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved by the US Food and Drug Administration in May 2022 for patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aimed to determine the rates of individual adverse events (AEs) related to 3\u00a0studied doses of tirzepatide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic review with meta-analysis including 5 databases (PubMed, Embase, CINAHL, Scopus, and Web of Science) for all clinical trials reporting AEs related to tirzepatide. The safety data from individual studies were extracted and analyzed through meta-regression to assess rates of individual AEs. Study quality assessment was performed using the National Heart, Lung, and Blood Institute Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten trials (6836 participants) were included. Gastrointestinal (GI) AEs were the most commonly reported AEs and were dose dependent 39% (95% CI, 35%-43%), 46% (95% CI, 42%-49%), and 49% (95% CI, 38%-60%) for the 5, 10, and 15\u2005mg dose, respectively. Among all GI AEs, nausea and diarrhea were most frequent at any dose of tirzepatide. Drug discontinuation due to AEs was highest with the 15\u2005mg dose of tirzepatide (10%). Incidence of mild hypoglycemia (blood glucose &amp;lt;\u200570\u2005mg\/dL) was highest with tirzepatide 10\u2005mg dose 22.6% (9.2%-39.8%). Rates of fatal AEs, severe hypoglycemia, acute pancreatitis, cholelithiasis, and cholecystitis were extremely low (\u2264\u20051%) across all doses of tirzepatide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tirzepatide is associated with a dose-dependent increase in incidence of GI AEs and AEs leading to drug discontinuation. Severe hypoglycemia, fatal AEs, acute pancreatitis, cholelithiasis, and cholecystitis are rare with this medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvad016","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T21:53:22Z","timestamp":1674770002000},"source":"Crossref","is-referenced-by-count":111,"title":["Adverse Events Related to Tirzepatide"],"prefix":"10.1210","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5631-1164","authenticated-orcid":false,"given":"Rahul","family":"Mishra","sequence":"first","affiliation":[{"name":"Department Hematology and Oncology, Cleveland Clinic Foundation , Cleveland, Ohio 44195 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4151-3246","authenticated-orcid":false,"given":"Rishi","family":"Raj","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, Pikeville Medical Center , Pikeville, Kentucky 41501 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-9099","authenticated-orcid":false,"given":"Ghada","family":"Elshimy","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, Medical College of Georgia, Augusta University , Augusta, Georgia 30912 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9009-8475","authenticated-orcid":false,"given":"Isain","family":"Zapata","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Rocky Vista University , Parker, Colorado 80112 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8306-6723","authenticated-orcid":false,"given":"Lakshmi","family":"Kannan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Pikeville Medical Center , Pikeville, Kentucky 41501 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6657-4726","authenticated-orcid":false,"given":"Priyanka","family":"Majety","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Virginia Commonwealth University , Richmond, Virginia 23298 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-7189","authenticated-orcid":false,"given":"Dinesh","family":"Edem","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, University of Arkansas for Medical Sciences , Little Rock, Arkansas 72205 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2761-2907","authenticated-orcid":false,"given":"Ricardo","family":"Correa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, Institute of Endocrinology and Metabolism, Cleveland Clinic , Cleveland, Ohio 44195 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"issue":"4","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/pr.108.000604","article-title":"The role of incretins in glucose homeostasis and diabetes treatment","volume":"60","author":"Kim","year":"2008","journal-title":"Pharmacol Rev"},{"issue":"10","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1210\/jcem-24-10-1076","article-title":"Plasma insulin response to oral and intravenous glucose administration","volume":"24","author":"Elrick","year":"1964","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01225454","article-title":"The incretin concept today","volume":"16","author":"Creutzfeldt","year":"1979","journal-title":"Diabetologia"},{"issue":"5","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"issue":"9548","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"issue":"Suppl 1","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20132022","volume":"45","author":"American Diabetes Association Professional Practice Committee.","year":"2022","journal-title":"Diabetes Care"},{"issue":"10","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan\u20142022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"issue":"5","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"issue":"4","key":"2023030705203772600_","first-page":"912","article-title":"Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations","volume":"76","author":"Nauck","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.2337\/db11-0979","article-title":"Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans","volume":"60","author":"Christensen","year":"2011","journal-title":"Diabetes"},{"issue":"9","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1210\/endo.139.9.6288","article-title":"Functional GIP receptors are present on adipocytes","volume":"139","author":"Yip","year":"1998","journal-title":"Endocrinology"},{"issue":"6","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"issue":"1","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther"},{"issue":"6","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"issue":"8","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40262-021-01012-2","article-title":"Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide","volume":"60","author":"Urva","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.13979","article-title":"Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens","volume":"22","author":"Fr\u00edas","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2023030705203772600_","volume-title":"Study Quality Assessment\u2014Adverse Events Related to Tirzepatide","author":"Raj","year":"2023","edition":"V1 ed"},{"issue":"10295","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"10160","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Fr\u00edas","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"10313","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"issue":"10300","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/dom.14572","article-title":"A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes","volume":"24","author":"Furihata","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2023030705203772600_","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1041044","article-title":"Optimal dose of tirzepatide for type 2 diabetes mellitus: a meta-analysis and trial sequential analysis","volume":"9","author":"Yu","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"issue":"6","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4103\/ijem.ijem_423_21","article-title":"Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: a Cochrane meta-analysis","volume":"25","author":"Dutta","year":"2021","journal-title":"Indian J Endocrinol Metab"},{"issue":"10","key":"2023030705203772600_","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3390\/ph14100991","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized phase II\/III trials","volume":"14","author":"Bhagavathula","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"2023030705203772600_","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102640","article-title":"Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Permana","year":"2022","journal-title":"Diabetes Metab Syndr"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvad016\/48930615\/bvad016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/7\/4\/bvad016\/49425543\/bvad016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/7\/4\/bvad016\/49425543\/bvad016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T15:59:52Z","timestamp":1679500792000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvad016\/7005432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,2,9]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvad016","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,1,26]]},"article-number":"bvad016"}}